- Home
- MRVI
as 03-31-2025 12:40pm EST
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 347.5M | IPO Year: | 2020 |
| Target Price: | $7.59 | AVG Volume (30 days): | 4.0M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.07 - $11.56 | Next Earning Date: | 03-18-2025 |
| Revenue: | $259,185,000 | Revenue Growth: | -10.30% |
| Revenue Growth (this year): | 3.8% | Revenue Growth (next year): | 11.15% |
Stock Insider Trading Activity of Maravai LifeSciences Holdings Inc. (MRVI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORESHACK KURT | MRVI | General Counsel | Jan 31 '25 | Sell | $5.03 | 25,000 | $125,750.00 | 167,618 |
Latest Maravai LifeSciences Holdings Inc. News
MRVI Breaking Stock News: Dive into MRVI Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Is Maravai LifeSciences Holdings, Inc. (MRVI) the Top Stock to Buy According to 12 West Capital Management?
TipRanks
9 days ago
Maravai Lifesciences price target lowered to $5 from $10 at Stifel
Motley Fool
10 days ago
Maravai LifeSciences (MRVI) Q4 2024 Earnings Call Transcript
MT Newswires
10 days ago
UBS Cuts Price Target on Maravai Lifesciences to $2.50 From $8, Keeps Neutral Rating
MT Newswires
10 days ago
Deutsche Bank Adjusts Price Target on Maravai Lifesciences to $5 From $10, Keeps Buy Rating
MT Newswires
13 days ago
Maravai Lifesciences Q4 Swings to Adjusted Loss, Revenue Declines
GlobeNewswire
13 days ago
Maravai Lifesciences Reports Fourth Quarter and Full Year 2024 Financial Results
Motley Fool
15 days ago
3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk
Compare MRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRVI Maravai LifeSciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.